Akebia therapeutics reports inducement grants under nasdaq listing rule 5635(c)(4)

Cambridge, mass., june 02, 2025 (globe newswire) -- akebia therapeutics®, inc. (nasdaq: akba), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted three newly-hired employees options to purchase an aggregate of 137,000 shares of akebia's common stock on may 30, 2025. the options were granted as an inducement material to each employee entering into employment with akebia. the options were granted in accordance with nasdaq listing rule 5635(c)(4).
NDAQ Ratings Summary
NDAQ Quant Ranking